Clinical trials recruiting in Baoding, China

Phase breakdown

Conditions recruiting in Baoding, China

Recruiting trials in Baoding, China

• A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
  NCT07406035 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT07111520 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Telitacicept in Lupus Nephritis
  NCT05680480 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
  NCT07169994 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT04928846 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
  NCT07140913 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
  NCT05894239 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT06417814 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
  NCT06989437 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
  NCT07062965 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
  NCT07673029 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Adjuvant Chemotherapy for High Malignant Prostate Cancer
  NCT06864533 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: Male
• Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
  NCT04270591 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
  NCT06300177 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder
  NCT07480525 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
  NCT06569524 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
  NCT05688696 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• JS207 Combination Therapy in Triple-negative Breast Cancer
  NCT07045311 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
  NCT06079983 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
  NCT07087223 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
  NCT07416474 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction
  NCT05583773 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
  NCT06712355 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
  NCT04930432 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
  NCT06799637 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
  NCT07139301 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
  NCT07139314 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Baoding, China?

37 recruiting trials have at least one study site in Baoding, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.